Notably, the choice of 5–6-month-old APP/PS1 mice is supported by previous studies demonstrating that early synaptic alterations, neuroinflammatory activation, and measurable cognitive deficits emerge as early as 4.5 months of age (Sanchez-Varo et al., 2021), thereby providing a critical window to evaluate prophylactic interventions. This evidence concerns the gene APP and Cognitive impairment.